April 3, 2018 / 11:34 AM / 4 months ago

BRIEF-Bio-Path Holdings Announces Interim Data From Phase 2 Clinical Trial Of Prexigebersen

April 3 (Reuters) - Bio Path Holdings Inc:

* PATH HOLDINGS ANNOUNCES INTERIM DATA FROM PHASE 2 CLINICAL TRIAL OF PREXIGEBERSEN IN COMBINATION WITH LOW DOSE CYTARABINE (LDAC) FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

* BIO PATH HOLDINGS INC - PREXIGEBERSEN PLUS LDAC WAS WELL-TOLERATED

* LEUKEMIC ACTIVITY IN NEARLY 50% OF EVALUABLE AML PATIENTS TREATED TO DATE​

* ‍ AMENDING PROTOCOL TO CHANGE DOSING SCHEDULE TO THAT USED IN PHASE 1B STUDY IN RELAPSED AND REFRACTORY AML PATIENTS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below